BRAF V600E 突变在结直肠癌（CRC）中是一个重要的生物标志物，约占所有结直肠癌病例的 10%。这一突变通常与肿瘤的侵袭性、预后不良以及对常规化疗的耐药性相关联[1]。研究显示，BRAF V600E 突变导致肿瘤细胞激活 MAPK ...

BRAF, a member of a serine/threonine kinase protein family, serves as an immediate downstream effector of RAS in the MAPK signaling cascade, a signal transduction pathway that transmits mitogenic ...

Building on this research, Professors Marshall and Richard Marais – who at the time was a colleague at the ICR – conducted further experiments on the pathway. They predicted that a protein called BRAF ...

A groundbreaking review highlights significant advancements in the understanding and treatment of cerebral vascular ...

but also sensitizes the tumors to specific inhibitors of pathway components. As we have reported, the BRAF and RAS mutant tumors are more sensitive to ERK pathway inhibition than the RAF/RAS wild type ...

FORE Biotherapeutics highlights pipeline achievements for its oncology programme; Provides objectives for 2025: Philadelphia Saturday, January 11, 2025, 17:00 Hrs [IST] FORE Bioth ...

BRAFTOVI is an oral small molecule kinase inhibitor that targets BRAF V600E. Inappropriate activation of proteins in the MAPK signaling pathway (RAS-RAF-MEK-ERK) has been shown to occur in certain ...